Translation Program

 

The Translation Program brings together researchers from other DRC Research Programs investigating fundamental processes leading to diabetes in humans with those translating preclinical findings to improvements in diabetes treatment. One strong component of the Translation Program includes researchers involved in the development of treatments for Type 1 diabetes. Researchers within the Translation Program also study the processes directly leading to diabetes in its most pertinent model organism, humans. These studies incorporate the ability to use a new generation of genomic and metabolic tools to investigate the underlying causes of disease and as well as the modes of action of drug therapies within the patient population. Human studies of the genetic and environmental factors affecting diabetes development and treatment represent another focus of the Translation Program. Thus, the Translation Program translates basic research to human treatment (“bench to bedside”) and studies humans to discover the most pertinent basic research areas (“bedside to bench”).

 

Translation Program Members and Research Activities:

Genetic and Environmental Factors

Mark Anderson, MD, PhD

Larry Fisher, PhD

Ira Goldfine, MD

Carl Grunfeld, MD, PhD

Wen-Chi Hsueh, MPH, PhD

Alka Kanaya, MD

Umesh Masharani, MD

Neil Risch, PhD

Christian Vaisse, MD, PhD

Jack Youngren, PhD

Transplantation and Autoimmunity

Jeffrey Bluestone, PhD

Stephen Gitelman, MD

Lewis Lanier, PhD

Andrew Posselt, MD, PhD

Peter Sayre, MD, PhD

Peter Stock, MD, PhD

Flavio Vincenti, MD

 

CENTER MEMBERS ARE REMINDED TO ACKNOWLEDGE DRC CENTER GRANT (P30 DK063720) CONTRIBUTIONS WITH ‘THIS RESEARCH WAS SUPPORTED BY GRANTS X, Y FROM NIH P30 DK063720'.